Getting some good news for a change, Johnson & Johnson ranks fourth among all companies in Newsweek's annual Green Rankings, ahead of other pharmaceuticals that made the top 100, including: Baxter, BMS, Allergan, Pfizer, Abbott, Lilly, Merck, and Hospira.
It's a matter of weeks now until we begin to see: a) to what degree the H1N1 pandemic will again ramp up; b) which manufacturers will have developed vaccines in time to address the need; and c) if those vaccines will work against the dominant strain that develops.
The California Board of Pharmacy has shown that it is willing to get tough with pharmacies that may have exacerbated the impact of the heparin crisis. It has fined nearly 100 hospital pharmacies who did not properly adhere to Baxter's heparin recall earlier this year.
This just in from the Chicago Tribune: only a small number of patient deaths connected to tainted heparin could conclusively be traced to material sold by Baxter. How many other ticking pharma QC time bombs are out there, waiting to explode? We'll examine this issue next month from analytical, regulatory...
OK, Rockville's a long way from Miami...but the analytical detective work that FDA, MIT scientists and some companies did into potential root causes of heparin contamination makes a great whodunit. C&EN, an outstanding publication, beat us to it by several months with this gem, published in late November.
We all know that physicians must distance themselves from patients to keep from becoming too emotionally involved in each case. Perhaps this applies to drug development and manufacturing as well, and industry profesionals may risk viewing adverse patient reactions as a mere statistic.
If the recent Science Board report on science within the Agency wasn't enough and you needed more evidence of the urgent need for better IT infrastructure, staffing and other resources for FDA, the Wall Street Journal released this bombshell this morning. Click here to read.